Recent advances in molecularly imprinted polymer-based electrochemical sensors

Li, Yixuan; Luo, Liuxiong; Kong, Yingqi; Li, Yujia; Wang, Quansheng; Wang, Mingqing; Li, Ying; Davenport, Andrew; Li, Bing

doi:10.1016/j.bios.2024.116018

Cited by 40 publications

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A Point‐of‐Care Sensing Platform for Multiplexed Detection of Chronic Kidney Disease Biomarkers Using Molecularly Imprinted Polymers

Li,

Luo,

Kong

et al. 2024

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is one of the most serious non‐communicable diseases affecting the population. In the early‐stages patients have no obvious symptoms, until it becomes life‐threatening leading end‐stage kidney failure. Therefore, it is important to early diagnose CKD to allow therapeutic interventions and progression monitoring. Here, a point‐of‐care (POC) sensing platform is reported for the simultaneous detection of three CKD biomarkers, namely creatinine, urea, and human serum albumin (HSA), using reduced graphene oxide/polydopamine‐molecularly imprinted polymer (rGO/PDA‐MIP) fabricated with novel surface‐molecularly imprinting technology. A multi‐channel electrochemical POC readout system with differential pulse voltammetry (DPV) function is developed, allowing the simultaneous detection of the three biomarkers, in combination with the surface‐MIP electrodes. This sensing platform achieves the record low limit‐of‐detection (LoD) at a femtomolar level for all three analytes, with wide detection ranges covering their physiological concentrations. Clinical validation is performed by measuring these analytes in serum and urine from healthy controls and patients with CKD. The average recovery rate is 81.8–119.1% compared to the results obtained from the hospital, while this platform is more cost‐effective, user‐friendly, and requires less sample‐to‐result time, showing the potential to be deployed in resource‐limited settings for the early diagnosis and tracking progression of CKD.

show abstract

A Point‐of‐Care Sensing Platform for Multiplexed Detection of Chronic Kidney Disease Biomarkers Using Molecularly Imprinted Polymers

Li,

Luo,

Kong

et al. 2024

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

show abstract

An Ultrasensitive Molecularly Imprinted Point‐Of‐Care Electrochemical Sensor for Detection of Glial Fibrillary Acidic Protein

Li,

Luo,

Senicar

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Accurate assessment of neurological disease through monitoring of biomarkers has been made possible using the antibody‐based assays. But these assays suffer from expensive development of antibody probes, reliance on complicated equipments, and high maintenance costs. Here, using the novel reduced graphene oxide/polydopamine‐molecularly imprinted polymer (rGO/PDA‐MIP) as the probe layer, a robust electrochemical sensing platform is demonstrated for the ultrasensitive detection of glial fibrillary acidic protein (GFAP), a biomarker for a range of neurological diseases. A miniaturized integrated circuit readout system is developed to interface with the electrochemical sensor, which empowers it with the potential to be used as a point‐of‐care (POC) diagnostic tool in primary clinical settings. This innovative platform demonstrated good sensitivity, selectivity, and stability, with imprinting factor evaluated as 2.8. A record low limit‐of‐detection (LoD) is down to 754.5 ag mL−1, with a wide dynamic range from 1 to 106 fg mL−1. The sensing platform is validated through the analysis of GFAP in clinical plasma samples, yielding a recovery rate range of 81.6–108.8% compared to Single Molecule Array (Simoa). This cost‐effective and user‐friendly sensing platform holds the potential to be deployed in primary and resource‐limited clinical settings for the assessment of neurological diseases.

show abstract